GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.
肥胖中 GLP-1 生理學及基於促胰島素的藥物在慢性體重管理中的發展。
Nat Metab 2024-08-19
A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
已核准並處於後期開發階段的胰高血糖素治療在超重和肥胖管理中的回顧。
Endocr Pract 2024-03-08
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists.
肥胖症和第二型糖尿病藥物治療的新發展 - GLP-1 受體激動劑的範疇內和範疇外。
Biomedicines 2024-06-27
Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?
遏制肥胖流行:GLP-1 受體激動劑是否應成為肥胖的標準治療?
Curr Cardiol Rep 2024-07-20
Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future.
臨床上基於胰高血糖素樣肽的療法在心代謝疾病管理中的應用:過去、現在與未來。
Med Res Rev 2024-08-14
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.
GLP-1 單一、雙重及三重受體激動劑在治療第二型糖尿病和肥胖症中的應用:敘述性回顧。
EClinicalMedicine 2024-09-16